Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 141

1.

Skin-related quality of life in HIV-infected patients on highly active antiretroviral therapy.

Mirmirani P, Maurer TA, Berger TG, Sands LP, Chren MM.

J Cutan Med Surg. 2002 Jan-Feb;6(1):10-5. Epub 2002 Jan 9.

PMID:
11896417
2.

Health-related quality of life and survival among HIV-infected patients receiving highly active antiretroviral therapy: a study of patients in the AIDS Therapy Evaluation in the Netherlands (ATHENA) Cohort.

de Boer-van der Kolk IM, Sprangers MA, Prins JM, Smit C, de Wolf F, Nieuwkerk PT.

Clin Infect Dis. 2010 Jan 15;50(2):255-63. doi: 10.1086/649216.

3.

Association between diarrhea and quality of life in HIV-infected patients receiving highly active antiretroviral therapy.

Tramarin A, Parise N, Campostrini S, Yin DD, Postma MJ, Lyu R, Grisetti R, Capetti A, Cattelan AM, Di Toro MT, Mastroianni A, Pignattari E, Mondardini V, Calleri G, Raise E, Starace F; Palladio Study Group.

Qual Life Res. 2004 Feb;13(1):243-50.

PMID:
15058804
4.

[Clinical status, adherence to HAART and quality of life in HIV-infected patients receiving antiretroviral treatment].

Ruiz-Pérez I, Olry de Labry-Lima A, López-Ruz MA, del Arco-Jiménez A, Rodríguez-Baño J, Causse-Prados M, Pasquau-Liaño J, Martín-Rico P, Prada-Pardal JL, de la Torre-Lima J, López-Gómez M, Marcos M, Muñoz N, Morales D, Muñoz I.

Enferm Infecc Microbiol Clin. 2005 Dec;23(10):581-5. Spanish.

PMID:
16324546
5.

Prevalence and impact of diarrhea on health-related quality of life in HIV-infected patients in the era of highly active antiretroviral therapy.

Siddiqui U, Bini EJ, Chandarana K, Leong J, Ramsetty S, Schiliro D, Poles M.

J Clin Gastroenterol. 2007 May-Jun;41(5):484-90.

PMID:
17450031
6.

Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.

Patel K, Hernán MA, Williams PL, Seeger JD, McIntosh K, Van Dyke RB, Seage GR 3rd; Pediatric AIDS Clinical Trials Group 219/219C Study Team.

Clin Infect Dis. 2008 Feb 15;46(4):507-15. doi: 10.1086/526524.

7.

Predictors for lower quality of life in the HAART era among HIV-infected men.

Liu C, Johnson L, Ostrow D, Silvestre A, Visscher B, Jacobson LP.

J Acquir Immune Defic Syndr. 2006 Aug 1;42(4):470-7.

PMID:
16810114
8.

Better quality of life with neuropsychological improvement on HAART.

Parsons TD, Braaten AJ, Hall CD, Robertson KR.

Health Qual Life Outcomes. 2006 Feb 24;4:11.

9.

The Changing Clinical Spectrum of Human Immunodeficiency Virus (HIV)-Related Oral Lesions in 1,000 Consecutive Patients: A 12-Year Study in a Referral Center in Mexico.

Ramírez-Amador V, Esquivel-Pedraza L, Sierra-Madero J, Anaya-Saavedra G, González-Ramírez I, Ponce-de-León S.

Medicine (Baltimore). 2003 Jan;82(1):39-50.

10.

Effects of depression and selective serotonin reuptake inhibitor use on adherence to highly active antiretroviral therapy and on clinical outcomes in HIV-infected patients.

Horberg MA, Silverberg MJ, Hurley LB, Towner WJ, Klein DB, Bersoff-Matcha S, Weinberg WG, Antoniskis D, Mogyoros M, Dodge WT, Dobrinich R, Quesenberry CP, Kovach DA.

J Acquir Immune Defic Syndr. 2008 Mar 1;47(3):384-90.

PMID:
18091609
11.

Oral lesions as clinical markers of highly active antiretroviral therapy failure: a nested case-control study in Mexico City.

Ramírez-Amador V, Ponce-de-León S, Anaya-Saavedra G, Crabtree Ramírez B, Sierra-Madero J.

Clin Infect Dis. 2007 Oct 1;45(7):925-32. Epub 2007 Aug 23.

12.
13.
14.

Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro.

Jevtović DO, Salemović D, Ranin J, Pesić I, Zerjav S, Djurković-Djaković O.

HIV Med. 2007 Mar;8(2):75-9.

15.

Effect of antiretroviral therapy on admissions of HIV-infected patients to an intensive care unit.

Palacios R, Hidalgo A, Reina C, de la Torre M, Márquez M, Santos J.

HIV Med. 2006 Apr;7(3):193-6.

16.

Cerebrovascular ischemic events in HIV-1-infected patients receiving highly active antiretroviral therapy: incidence and risk factors.

Corral I, Quereda C, Moreno A, Pérez-Elías MJ, Dronda F, Casado JL, Muriel A, Masjuán J, Alonso-de-Leciñana M, Moreno S.

Cerebrovasc Dis. 2009;27(6):559-63. doi: 10.1159/000214219. Epub 2009 Apr 24.

PMID:
19390181
17.

Is antiretroviral therapy causing long-term liver damage? A comparative analysis of HIV-mono-infected and HIV/hepatitis C co-infected cohorts.

Moodie EE, Pant Pai N, Klein MB.

PLoS One. 2009;4(2):e4517. doi: 10.1371/journal.pone.0004517. Epub 2009 Feb 18.

18.

Impacts of HIV infection and HAART use on quality of life.

Liu C, Ostrow D, Detels R, Hu Z, Johnson L, Kingsley L, Jacobson LP.

Qual Life Res. 2006 Aug;15(6):941-9.

PMID:
16900275
19.

Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Delta32 deletion.

Laurichesse JJ, Persoz A, Theodorou I, Rouzioux C, Delfraissy JF, Meyer L.

HIV Med. 2007 May;8(4):213-9.

20.

Incidence and prognosis of CMV disease in HIV-infected patients before and after introduction of combination antiretroviral therapy.

Salzberger B, Hartmann P, Hanses F, Uyanik B, Cornely OA, Wöhrmann A, Fätkenheuer G.

Infection. 2005 Oct;33(5-6):345-9.

PMID:
16258865
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk